Skip to main content
. 2010 Aug;21(8):1290–1298. doi: 10.1681/ASN.2009101025

Figure 4.

Figure 4.

A high dose combined with a booster dose of the anti-Fx1A antibody induces a stable PHN disease model with a long-lasting and high level of proteinuria. The antibody was intravenously injected at a volume of 1.0 (black bars) or 1.5 ml (gray bars) at day 0 or a volume of 1.5 and 0.5 ml at day 0 and 7 (transparent bars), respectively. Spot urine was collected on day 15, 21, and 28 and analyzed for urinary albumin and creatinine content. Data are presented as mean ± SEM (n = 8).